BP
Boston Partners disclosed a 6.2% stake in CTKB
Boston Partners reported owning 6.2% of Cytek Biosciences, Inc. (CTKB) (8,002,638 shares) in a Schedule 13G filed Nov 13, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Nov 13, 2026
- Source
- Schedule 13G